Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dinow
Mito-shi (Mito City), Ibaraki Prefecture, Japandinow.net ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Dinow has developed a proprietary platform to assess DNA damage in human biospecimens, primarily using the γ-H2AX assay. The company’s technology enables individuals to monitor their health status—especially regarding radiation exposure—by quantifying cellular DNA damage. This approach aims to provide peace of mind and actionable information following events such as nuclear accidents or other sources of radiation[1].
- Therapeutic areas
- Other
- Modalities
- DeviceDiagnostic assay
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Dinow.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dinow.